Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2− Early-stage Breast Cancer

Background Weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) demonstrated greater efficacy with less toxicity than docetaxel in metastatic breast cancer. We conducted a randomized phase II to compare these regimens as neoadjuvant chemotherapy for HER2− early-stage breast cancer. Patients and Methods Stage I-III human epidermal growth factor receptor-negative (HER2−) breast cancer patients were included in the present trial and...